LoginSignup
AXS

Axsome

Stock
Stock
ISIN: US05464T1043
Ticker: AXSM
US05464T1043
AXSM

Price

Price

Frequently asked questions

What is Axsome's market capitalization?

The market capitalization of Axsome is $4.58B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Axsome?

Axsome's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$6.536. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Axsome's stock?

Currently, 16 analysts cover Axsome's stock, with a consensus target price of $125.73. Analyst ratings provide insights into the stock's expected performance.

What is Axsome's revenue over the trailing twelve months?

Over the trailing twelve months, Axsome reported a revenue of $338.46M.

What is the EBITDA for Axsome?

Axsome's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$298.59M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Axsome?

Axsome has a free cash flow of -$132.82M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Axsome's stock?

The 5-year beta for Axsome is 1.17. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Axsome have, and what sector and industry does it belong to?

Axsome employs approximately 545 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Axsome's shares?

The free float of Axsome is 39.63M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $4.58B

5Y beta

 1.17

EPS (TTM)

 -$6.536

Free Float

 39.63M

Revenue (TTM)

 $338.46M

EBITDA (TTM)

 -$298.59M

Free Cashflow (TTM)

 -$132.82M

Pricing

1D span
$89.64$99.37
52W span
$60.28$105.00

Analyst Ratings

The price target is $125.73 and the stock is covered by 16 analysts.

Buy

14

Hold

2

Sell

0

Information

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.

545

Biotechnology & Drugs

Health Care

Identifier

ISIN

US05464T1043

Primary Ticker

AXSM

Knockouts

Join the conversation
Sign upLogin